Nobutaka Kataoka

Kyoto, 6028566, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database.

Prevalence and molecular landscape of NRG1 fusions in Japanese solid tumors: a nationwide data analysis using the C-CAT database.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 05, 2025

CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.

CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.

Journal: Translational lung cancer research

Published: March 01, 2024

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.

Journal: Frontiers in oncology

Published: September 28, 2023

First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.

First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.

Journal: Cancers

Published: September 22, 2023

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report.

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report.

Journal: Respirology case reports

Published: June 24, 2023

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.

Journal: Medicina (Kaunas, Lithuania)

Published: May 03, 2022

Atezolizumab in combination with carboplatin plus nab-paclitaxel for managing combined large-cell neuroendocrine carcinoma: A case report.

Atezolizumab in combination with carboplatin plus nab-paclitaxel for managing combined large-cell neuroendocrine carcinoma: A case report.

Journal: Respirology case reports

Published: March 16, 2022

Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: A case report.

Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: A case report.

Journal: Respirology case reports

Published: August 15, 2021

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report.

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report.

Journal: Medicina (Kaunas, Lithuania)

Published: April 18, 2021

Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report.

Nasogastric administration of osimertinib suspension for an epidermal growth factor receptor-mutated lung cancer causing an esophageal stricture: case report.

Journal: Annals of palliative medicine

Published: April 18, 2021

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.

Journal: Frontiers in oncology

Published: February 05, 2021

Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.

Early responders within seven days of dupilumab treatment for severe asthma evaluated by patient-reported outcome: a pilot study.

Journal: Multidisciplinary respiratory medicine

Published: November 21, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026